627 related articles for article (PubMed ID: 18305481)
41. Nucleic acid recognizing Toll-like receptors and autoimmunity.
von Landenberg P; Bauer S
Curr Opin Immunol; 2007 Dec; 19(6):606-10. PubMed ID: 18060756
[TBL] [Abstract][Full Text] [Related]
42. Essential role for Toll-like receptor 7 (TLR7)-unique cysteines in an intramolecular disulfide bond, proteolytic cleavage and RNA sensing.
Kanno A; Yamamoto C; Onji M; Fukui R; Saitoh S; Motoi Y; Shibata T; Matsumoto F; Muta T; Miyake K
Int Immunol; 2013 Jul; 25(7):413-22. PubMed ID: 23446849
[TBL] [Abstract][Full Text] [Related]
43. The in vitro and in ovo responses of chickens to TLR9 subfamily ligands.
Jenkins KA; Lowenthal JW; Kimpton W; Bean AG
Dev Comp Immunol; 2009 May; 33(5):660-7. PubMed ID: 19100284
[TBL] [Abstract][Full Text] [Related]
44. Necrotizing lymphadenitis may be induced by overexpression of Toll-like receptor7 (TLR7) caused by reduced TLR9 transport in plasmacytoid dendritic cells (PDCs).
Asano S; Sato H; Mori K; Yamazaki K; Naito H; Suzuki H
J Clin Exp Hematop; 2021 Jun; 61(2):85-92. PubMed ID: 33994431
[TBL] [Abstract][Full Text] [Related]
45. Porin-incorporated liposome induces Toll-like receptors 2- and 6-dependent maturation and type 1 response of dendritic cell.
Banerjee P; Biswas A; Biswas T
Int Immunol; 2008 Dec; 20(12):1551-63. PubMed ID: 18931363
[TBL] [Abstract][Full Text] [Related]
46. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
[TBL] [Abstract][Full Text] [Related]
47. A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.
Iavarone C; Ramsauer K; Kubarenko AV; Debasitis JC; Leykin I; Weber AN; Siggs OM; Beutler B; Zhang P; Otten G; D'Oro U; Valiante NM; Mbow ML; Visintin A
J Immunol; 2011 Apr; 186(7):4213-22. PubMed ID: 21383246
[TBL] [Abstract][Full Text] [Related]
48. Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma.
Erridge C; Burdess A; Jackson AJ; Murray C; Riggio M; Lappin D; Milligan S; Spickett CM; Webb DJ
Eur J Clin Invest; 2008 Oct; 38(10):713-20. PubMed ID: 18837796
[TBL] [Abstract][Full Text] [Related]
49. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA.
Barton GM; Kagan JC; Medzhitov R
Nat Immunol; 2006 Jan; 7(1):49-56. PubMed ID: 16341217
[TBL] [Abstract][Full Text] [Related]
50. Polymorphisms and expression of toll-like receptors in autoimmune thyroid diseases.
Inoue N; Katsumata Y; Watanabe M; Ishido N; Manabe Y; Watanabe A; Masutani R; Hidaka Y; Iwatani Y
Autoimmunity; 2017 May; 50(3):182-191. PubMed ID: 28013570
[TBL] [Abstract][Full Text] [Related]
51. Cathepsins are required for Toll-like receptor 9 responses.
Matsumoto F; Saitoh S; Fukui R; Kobayashi T; Tanimura N; Konno K; Kusumoto Y; Akashi-Takamura S; Miyake K
Biochem Biophys Res Commun; 2008 Mar; 367(3):693-9. PubMed ID: 18166152
[TBL] [Abstract][Full Text] [Related]
52. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer.
Hirsch I; Caux C; Hasan U; Bendriss-Vermare N; Olive D
Trends Immunol; 2010 Oct; 31(10):391-7. PubMed ID: 20832362
[TBL] [Abstract][Full Text] [Related]
53. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells.
Sepulveda FE; Maschalidi S; Colisson R; Heslop L; Ghirelli C; Sakka E; Lennon-Duménil AM; Amigorena S; Cabanie L; Manoury B
Immunity; 2009 Nov; 31(5):737-48. PubMed ID: 19879164
[TBL] [Abstract][Full Text] [Related]
54. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo.
Lamphier M; Zheng W; Latz E; Spyvee M; Hansen H; Rose J; Genest M; Yang H; Shaffer C; Zhao Y; Shen Y; Liu C; Liu D; Mempel TR; Rowbottom C; Chow J; Twine NC; Yu M; Gusovsky F; Ishizaka ST
Mol Pharmacol; 2014 Mar; 85(3):429-40. PubMed ID: 24342772
[TBL] [Abstract][Full Text] [Related]
55. Immunodeficiency: UNC-93B gets a toll call.
Conley ME
Trends Immunol; 2007 Mar; 28(3):99-101. PubMed ID: 17240194
[TBL] [Abstract][Full Text] [Related]
56. Toll-like receptor 9 trafficking and signaling for type I interferons requires PIKfyve activity.
Hayashi K; Sasai M; Iwasaki A
Int Immunol; 2015 Sep; 27(9):435-45. PubMed ID: 25925170
[TBL] [Abstract][Full Text] [Related]
57. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
Wang D; Bhagat L; Yu D; Zhu FG; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2009 Jan; 52(2):551-8. PubMed ID: 19102653
[TBL] [Abstract][Full Text] [Related]
58. Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms.
Pelka K; Phulphagar K; Zimmermann J; Stahl R; Schmid-Burgk JL; Schmidt T; Spille JH; Labzin LI; Agrawal S; Kandimalla ER; Casanova JL; Hornung V; Marshak-Rothstein A; Höning S; Latz E
J Immunol; 2014 Oct; 193(7):3257-61. PubMed ID: 25187660
[TBL] [Abstract][Full Text] [Related]
59. The role of UNC93B1 protein in surface localization of TLR3 receptor and in cell priming to nucleic acid agonists.
Pohar J; Pirher N; Benčina M; Manček-Keber M; Jerala R
J Biol Chem; 2013 Jan; 288(1):442-54. PubMed ID: 23166319
[TBL] [Abstract][Full Text] [Related]
60. An oligodeoxynucleotide with CCT repeats restrains CpG ODN-induced TLR9 trafficking.
Zhang X; Sun W; Wu X; Wang H; Yan Y; Guo S; Song D; Li H; Gao S; Wang L; Yu Y; Wang L
Curr Pharm Biotechnol; 2014; 15(9):780-9. PubMed ID: 25374030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
